Results of a phase III study concluding that rituximab maintenance can be more effective than watchful waiting.
Home / Resource Library / Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial